397 related articles for article (PubMed ID: 31859249)
1. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.
You I; Erickson EC; Donovan KA; Eleuteri NA; Fischer ES; Gray NS; Toker A
Cell Chem Biol; 2020 Jan; 27(1):66-73.e7. PubMed ID: 31859249
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
Yu X; Xu J; Xie L; Wang L; Shen Y; Cahuzac KM; Chen X; Liu J; Parsons RE; Jin J
J Med Chem; 2021 Dec; 64(24):18054-18081. PubMed ID: 34855399
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
Blake JF; Xu R; Bencsik JR; Xiao D; Kallan NC; Schlachter S; Mitchell IS; Spencer KL; Banka AL; Wallace EM; Gloor SL; Martinson M; Woessner RD; Vigers GP; Brandhuber BJ; Liang J; Safina BS; Li J; Zhang B; Chabot C; Do S; Lee L; Oeh J; Sampath D; Lee BB; Lin K; Liederer BM; Skelton NJ
J Med Chem; 2012 Sep; 55(18):8110-27. PubMed ID: 22934575
[TBL] [Abstract][Full Text] [Related]
4. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
5. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
Lin J; Sampath D; Nannini MA; Lee BB; Degtyarev M; Oeh J; Savage H; Guan Z; Hong R; Kassees R; Lee LB; Risom T; Gross S; Liederer BM; Koeppen H; Skelton NJ; Wallin JJ; Belvin M; Punnoose E; Friedman LS; Lin K
Clin Cancer Res; 2013 Apr; 19(7):1760-72. PubMed ID: 23287563
[TBL] [Abstract][Full Text] [Related]
6. Recent progress towards clinically relevant ATP-competitive Akt inhibitors.
Huck BR; Mochalkin I
Bioorg Med Chem Lett; 2017 Jul; 27(13):2838-2848. PubMed ID: 28506751
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
[TBL] [Abstract][Full Text] [Related]
8. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
10. Microsecond molecular dynamics simulations provide insight into the ATP-competitive inhibitor-induced allosteric protection of Akt kinase phosphorylation.
Mou L; Cui T; Liu W; Zhang H; Cai Z; Lu S; Gao G
Chem Biol Drug Des; 2017 May; 89(5):723-731. PubMed ID: 27797456
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
12. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
Tong B; Spradlin JN; Novaes LFT; Zhang E; Hu X; Moeller M; Brittain SM; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
ACS Chem Biol; 2020 Jul; 15(7):1788-1794. PubMed ID: 32568522
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
15. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.
Zhu CL; Luo X; Tian T; Rao Z; Wang H; Zhou Z; Mi T; Chen D; Xu Y; Wu Y; Che J; Zhou Y; Li J; Dong X
Eur J Med Chem; 2022 Aug; 238():114459. PubMed ID: 35635954
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
17. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A
Cancer Discov; 2017 Jan; 7(1):102-113. PubMed ID: 27872130
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
20. Selective degradation of CDK6 by a palbociclib based PROTAC.
Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]